CD19 and B-cell non-Hodgkin lymphoma: Ye et al. designed lipid nanoparticles (LNPs) that contain CAR mRNA and generate anti-CD19 CAR M by transferring LNPs to murine primary macrophages, demonstrating notable cytotoxic effects against human B-cell lymphoma in-vitro (89).